Axsome Therapeutics (AXSM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.75 (+1.78%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Axsome Therapeutics (AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Key Insights

Critical company metrics and information
  • Share Price

    $100.10
  • Market Cap

    $4.85 Billion
  • Total Outstanding Shares

    48.46 Million Shares
  • Total Employees

    589
  • Dividend

    No dividend
  • IPO Date

    November 19, 2015
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.axsome.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$43.59 Million
Net Cash Flow From Investing Activities$247000.00
Net Cash Flow From Financing Activities, Continuing$43.59 Million
Net Cash Flow From Operating Activities, Continuing$-132.57 Million
Net Cash Flow, Continuing$-89.22 Million
Net Cash Flow From Operating Activities$-132.57 Million
Net Cash Flow$-89.22 Million
Net Cash Flow From Investing Activities, Continuing$247000.00

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$6.58
Net Income/Loss$-310.95 Million
Net Income/Loss Available To Common Stockholders, Basic$-310.95 Million
Income Tax Expense/Benefit$325000.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Diluted Average Shares$96.26 Million
Preferred Stock Dividends And Other Adjustments$0.00
Operating Expenses$644.68 Million
Other Operating Expenses$96.91 Million
Costs And Expenses$644.68 Million
Income/Loss From Continuing Operations After Tax$-310.95 Million
Income/Loss From Continuing Operations Before Tax$-311.28 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Operating Income/Loss$-306.22 Million
Research and Development$162.87 Million
Basic Average Shares$96.26 Million
Diluted Earnings Per Share$6.58
Selling, General, and Administrative Expenses$384.90 Million
Benefits Costs and Expenses$649.74 Million
Net Income/Loss Attributable To Parent$-310.95 Million
Revenues$338.46 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$196.19 Million
Wages$19.37 Million
Other Non-current Assets$33.16 Million
Current Assets$479.11 Million
Inventory$14.27 Million
Equity$92.90 Million
Fixed Assets$683000.00
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$64.25 Million
Noncurrent Assets$82.34 Million
Other Current Liabilities$112.57 Million
Noncurrent Liabilities$272.37 Million
Intangible Assets$48.50 Million
Other Current Assets$464.85 Million
Liabilities$468.56 Million
Equity Attributable To Parent$92.90 Million
Assets$561.46 Million
Liabilities And Equity$561.46 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.